AP Biosciences, Inc. (TPEX:6945)
Taiwan
· Delayed Price · Currency is TWD 186.50
0.00 (0.00%)
Apr 29, 2026, 2:00 PM CST
AP Biosciences Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | - | - | 32.25 | - | 6.99 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -94.92% | Upgrade
|
| Gross Profit | - | - | 32.25 | - | 6.99 | Upgrade
|
| Selling, General & Admin | 86.61 | 73.11 | 43.13 | 34.82 | 19.9 | Upgrade
|
| Research & Development | 369.77 | 365.95 | 336.6 | 262.68 | 173.81 | Upgrade
|
| Operating Expenses | 456.38 | 439.06 | 379.73 | 297.5 | 193.71 | Upgrade
|
| Operating Income | -456.38 | -439.06 | -347.48 | -297.5 | -186.72 | Upgrade
|
| Interest Expense | -1.42 | -1.65 | -1.2 | - | - | Upgrade
|
| Interest & Investment Income | 19.56 | 13.52 | 10.03 | 2.58 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.38 | 4.26 | -0.83 | 6.27 | -1.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.08 | 0.18 | 0.19 | 0.11 | 0.21 | Upgrade
|
| EBT Excluding Unusual Items | -443.54 | -422.75 | -339.29 | -288.54 | -187.61 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.23 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0 | - | - | Upgrade
|
| Pretax Income | -444.77 | -422.75 | -339.3 | -288.54 | -187.61 | Upgrade
|
| Net Income | -444.77 | -422.75 | -339.3 | -288.54 | -187.61 | Upgrade
|
| Net Income to Common | -444.77 | -422.75 | -339.3 | -288.54 | -187.61 | Upgrade
|
| Shares Outstanding (Basic) | 85 | 75 | 65 | 53 | 24 | Upgrade
|
| Shares Outstanding (Diluted) | 85 | 75 | 65 | 53 | 24 | Upgrade
|
| Shares Change (YoY) | 13.06% | 16.28% | 22.98% | 118.32% | 75.62% | Upgrade
|
| EPS (Basic) | -5.23 | -5.61 | -5.24 | -5.48 | -7.78 | Upgrade
|
| EPS (Diluted) | -5.23 | -5.61 | -5.24 | -5.48 | -7.78 | Upgrade
|
| Free Cash Flow | -377.12 | -363.41 | -332.65 | -277.1 | -172.58 | Upgrade
|
| Free Cash Flow Per Share | -4.43 | -4.83 | -5.14 | -5.26 | -7.16 | Upgrade
|
| Gross Margin | - | - | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | - | - | -1077.35% | - | -2670.06% | Upgrade
|
| Profit Margin | - | - | -1051.98% | - | -2682.77% | Upgrade
|
| Free Cash Flow Margin | - | - | -1031.37% | - | -2467.90% | Upgrade
|
| EBITDA | -443.1 | -433.93 | -344.01 | -290.07 | -178.33 | Upgrade
|
| D&A For EBITDA | 13.28 | 5.13 | 3.46 | 7.42 | 8.39 | Upgrade
|
| EBIT | -456.38 | -439.06 | -347.48 | -297.5 | -186.72 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.